These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 21251627)

  • 1. Long-term follow-up of drug-eluting stents placed in the setting of ST-segment elevation myocardial infarction.
    Ziada KM; Charnigo R; Moliterno DJ
    JACC Cardiovasc Interv; 2011 Jan; 4(1):39-41. PubMed ID: 21251627
    [No Abstract]   [Full Text] [Related]  

  • 2. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial.
    Vink MA; Dirksen MT; Suttorp MJ; Tijssen JG; van Etten J; Patterson MS; Slagboom T; Kiemeneij F; Laarman GJ
    JACC Cardiovasc Interv; 2011 Jan; 4(1):24-9. PubMed ID: 21251625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON angioplasty).
    Spaulding C; Teiger E; Commeau P; Varenne O; Bramucci E; Slama M; Beatt K; Tirouvanziam A; Polonski L; Stella PR; Clugston R; Fajadet J; de Boisgelin X; Bode C; Carrié D; Erglis A; Merkely B; Hosten S; Cebrian A; Wang P; Stoll HP; Henry P
    JACC Cardiovasc Interv; 2011 Jan; 4(1):14-23. PubMed ID: 21251624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sirolimus- versus paclitaxel-eluting stents for unselected patients with coronary artery disease.
    Park SJ
    Catheter Cardiovasc Interv; 2011 Jan; 77(1):13-4. PubMed ID: 21181967
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion study.
    Wijnbergen I; Helmes H; Tijssen J; Brueren G; Peels K; van Dantzig JM; Van' t Veer M; Koolen JJ; Pijls NH; Michels R
    JACC Cardiovasc Interv; 2012 Mar; 5(3):313-22. PubMed ID: 22440498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should we routinely use drug-eluting stents for acute myocardial infarction? Let's wait and see.
    Grines CL; Goldstein JA; Safian RD
    JACC Cardiovasc Interv; 2008 Apr; 1(2):136-8. PubMed ID: 19463291
    [No Abstract]   [Full Text] [Related]  

  • 7. Paclitaxel- versus sirolimus-eluting stents for treatment of ST-segment elevation myocardial infarction: with analyses for diabetic and nondiabetic subpopulation.
    Cho Y; Yang HM; Park KW; Chung WY; Choi DJ; Seo WW; Jeong KT; Chae SC; Lee MY; Hur SH; Chae JK; Seong IW; Yoon JH; Oh SK; Kim DI; Park KS; Rha SW; Jang YS; Bae JH; Hong TJ; Cho MC; Kim YJ; Jeong MH; Kim MJ; Park SK; Chae IH; Kim HS;
    JACC Cardiovasc Interv; 2010 May; 3(5):498-506. PubMed ID: 20488406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Kounis syndrome in everolimus-eluting stents and paclitaxel-eluting stents.
    Kounis NG; Giannopoulos S; Goudevenos JA
    Catheter Cardiovasc Interv; 2010 Dec; 76(7):1076-7; author reply 1078. PubMed ID: 21086494
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of drug-eluting stents in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a meta-analysis of randomised trials and an adjusted indirect comparison.
    Piscione F; Piccolo R; Cassese S; Galasso G; De Rosa R; D'Andrea C; Chiariello M
    EuroIntervention; 2010 Feb; 5(7):853-60. PubMed ID: 20142203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-eluting versus bare-metal stents in the treatment of patients with ST-segment elevation myocardial infarction.
    Hannan EL; Racz M; Walford G; Holmes DR; Jones RH; Sharma S; Katz S; King SB
    JACC Cardiovasc Interv; 2008 Apr; 1(2):129-35. PubMed ID: 19463290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. If I've heard it once, I've heard it (not yet) a hundred times.
    Butman SM
    Catheter Cardiovasc Interv; 2011 Mar; 77(4):502. PubMed ID: 21351224
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug-eluting stents for ST-segment elevation myocardial infarction: treatment of choice or is discretion the better part of valor?
    Rihal CS
    JACC Cardiovasc Interv; 2008 Jun; 1(3):233-5. PubMed ID: 19463305
    [No Abstract]   [Full Text] [Related]  

  • 14. 3-year follow-up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) trial.
    Holmes DR; Teirstein PS; Satler L; Sketch MH; Popma JJ; Mauri L; Wang HP; Schleckser PA; Cohen SA;
    JACC Cardiovasc Interv; 2008 Aug; 1(4):439-48. PubMed ID: 19463342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
    Leon MB; Nikolsky E; Cutlip DE; Mauri L; Liberman H; Wilson H; Patterson J; Moses J; Kandzari DE;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical impact of sirolimus-eluting stent in ST-segment elevation myocardial infarction: a meta-analysis of randomized clinical trials.
    Piscione F; Piccolo R; Cassese S; Galasso G; Chiariello M
    Catheter Cardiovasc Interv; 2009 Aug; 74(2):323-32. PubMed ID: 19360858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent).
    Ellis SG; Stone GW; Cox DA; Hermiller J; O'Shaughnessy C; Mann T; Turco M; Caputo R; Bergin PJ; Bowman TS; Baim DS;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1248-59. PubMed ID: 20129552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. More openness and a little less strut: two good ideas for stents and the people who implant them.
    Morrison DA
    Catheter Cardiovasc Interv; 2010 Nov; 76(5):652-3. PubMed ID: 20976746
    [No Abstract]   [Full Text] [Related]  

  • 19. The efficacy of drug-eluting stents in women: a window of opportunity.
    Jacobs AK
    JACC Cardiovasc Interv; 2009 Jul; 2(7):611-3. PubMed ID: 19628182
    [No Abstract]   [Full Text] [Related]  

  • 20. Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials.
    Palmerini T; Kirtane AJ; Serruys PW; Smits PC; Kedhi E; Kereiakes D; Sangiorgi D; Bacchi Reggiani L; Kaiser C; Kim HS; De Waha A; Ribichini F; Stone GW
    Circ Cardiovasc Interv; 2012 Jun; 5(3):357-64. PubMed ID: 22668554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.